



## **Texas Governor Rick Perry Praises Receptor Logic at Visit to the Abilene Life Sciences Accelerator (ALSA)**

**Abilene, Texas - January 26, 2010** - Governor Rick Perry visited the new Abilene Life Sciences Accelerator (ALSA) on January 26 and praised the business incubator and its first tenant, biopharmaceutical company Receptor Logic. The press conference took place in the Receptor Logic lab at the ALSA.

In his remarks the governor said, "I think we have created an unmatched environment of innovation in this state, and it's people like you all who have devoted your lives to seeing these types of programs go forward."

Receptor Logic founder and Chief Scientist, Jon Weidanz, Ph.D., acknowledged the role that Governor Perry has played in raising awareness of the significance of biotechnology for the State of Texas and the support of the Abilene community. Dr. Weidanz stated, "Receptor Logic has the distinction of several 'firsts' related to Abilene. We are the first life sciences company to make Abilene our headquarters; the first Abilene company to receive a Texas Emerging Technology Fund (TETF) investment of \$2 million; and the first company to become a tenant of the city's business incubator, the ALSA."

Abilene Mayor Norm Archibald, also praised the positive effect the life sciences development program has had on the City of Abilene. "This is a new sector of our economy that has come into play that has provided jobs," Archibald said.

Gregory Pogue, Ph.D., President of Receptor Logic, commented, "We have been fortunate in the tremendous support Receptor Logic has received at both the state and local level. Now, we begin a new chapter in our company's progress as a tenant of the ALSA. Our goal is to make a significant contribution to human healthcare through our T-Cell Receptor mimic technology and to fulfill a leadership role in biopharmaceutical advancement. In achieving this goal, we will also benefit the economic development of Abilene, the West Texas Region and our state."

Receptor Logic, Inc. is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRm) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. Receptor Logic, Inc. is an Emergent Technologies Inc. (ETI) portfolio company, to which ETI provides management services.